ConductScience.org, home

Paper37147404

Parkinson's disease therapy: what lies ahead?

Wolff A and 7 others. J Neural Transm (Vienna), 2023. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Parkinson's disease therapy: what lies ahead? Papers, record 37147404. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37147404

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Parkinson's disease therapy: what lies ahead?
PubMed
Journal
J Neural Transm (Vienna)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
2.84
iCite
Revised in PubMed
2024-09-18
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wolff AAndreas
2Schumacher NUNicolas U
3Pürner DDominik
4Machetanz GGerrit
5Demleitner AFAntonia F
6Feneberg EEmily
7Hagemeier MMaike
8Lingor PPaulhttps://orcid.org/0000-0001-9362-7096

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Parkinson DiseaseMajor topic
Humans
Dopamine
Disease Progression

References226

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132651333The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?J Parkinsons Dis2020https://conductscience.org/library/papers/32651333PubMed
231211166α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease.Ann Clin Transl Neurol2019https://conductscience.org/library/papers/31211166PubMed
326117366Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.Brain2015https://conductscience.org/library/papers/26117366PubMed
427548849Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.Mov Disord2016https://conductscience.org/library/papers/27548849PubMed
518625222Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.Exp Neurol2008https://conductscience.org/library/papers/18625222PubMed
633074190Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects.J Parkinsons Dis2021https://conductscience.org/library/papers/33074190PubMed
730706414
Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
J Neuroimmune Pharmacol2019https://conductscience.org/library/papers/30706414PubMed
836402160Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.Lancet Neurol2022https://conductscience.org/library/papers/36402160PubMed
933566871Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson's disease: Analysis of the PPMI data.PLoS One2021https://conductscience.org/library/papers/33566871PubMed
1033772855Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.Ann Neurol2021https://conductscience.org/library/papers/33772855PubMed
1133855335Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder.Brain2021https://conductscience.org/library/papers/33855335PubMed
1231123700Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset.NPJ Parkinsons Dis2019https://conductscience.org/library/papers/31123700PubMed
1332116488Motion Biomarkers Showing Maximum Contrast Between Healthy Subjects and Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus. A Pilot Study.Front Neurosci2019https://conductscience.org/library/papers/32116488PubMed
1432059811Long-term unsupervised mobility assessment in movement disorders.Lancet Neurol2020https://conductscience.org/library/papers/32059811PubMed
1535350553Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study.Brain Commun2022https://conductscience.org/library/papers/35350553PubMed
1728233927Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.Mov Disord2017https://conductscience.org/library/papers/28233927PubMed
1826239690Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.J Am Med Dir Assoc2015https://conductscience.org/library/papers/26239690PubMed
1934659081A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.Front Neurol2021https://conductscience.org/library/papers/34659081PubMed
2034289275Trial of Pimavanserin in Dementia-Related Psychosis.N Engl J Med2021https://conductscience.org/library/papers/34289275PubMed
2136036203Magnetic Resonance-Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson's Disease: A Pilot Study.Mov Disord2022https://conductscience.org/library/papers/36036203PubMed

See all 226 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
42339433Mild cognitive impairment in Parkinson's disease: current view.Front Cognit2024https://conductscience.org/library/papers/42339433PubMed
42133016The future digital outpatient clinic for movement disorders: from technological innovation to ethical and systemic implementation-a position paper.J Neural Transm (Vienna)2026https://conductscience.org/library/papers/42133016PubMed
41822652Potential Synergistic Roles of Ketogenic Diet and Stem Cell Therapy in Parkinson's Disease: A Narrative Review.Cureus2026https://conductscience.org/library/papers/41822652PubMed
41737007Neural correlates of prospective memory in Parkinson's disease: a high-density EEG study.Front Aging Neurosci2026https://conductscience.org/library/papers/41737007PubMed
41526401Data-driven clinical decision support tool for diagnosing mild cognitive impairment in Parkinson's disease.NPJ Parkinsons Dis2026https://conductscience.org/library/papers/41526401PubMed
41383702Beyond boundaries: Neuroprotective effects of steroids and ecdysteroids in SH-SY5Y cells - A systematic review.Neuroprotection2024https://conductscience.org/library/papers/41383702PubMed
41030936Validation of a Mitochondrial Polygenic Score for Parkinson's Disease.medRxiv2025https://conductscience.org/library/papers/41030936PubMed
40942672InfraRed Thermographic Measurements in Parkinson's Disease Subjects: Preliminary Results.Sensors (Basel)2025https://conductscience.org/library/papers/40942672PubMed
40529404Parkinson's Elevated: improving healthspan.Front Sports Act Living2025https://conductscience.org/library/papers/40529404PubMed
40336538Role and mechanism of molecular hydrogen in the treatment of Parkinson's diseases.Front Neurosci2025https://conductscience.org/library/papers/40336538PubMed
40289580From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease.J Parkinsons Dis2026https://conductscience.org/library/papers/40289580PubMed
40146621IGF2-Reprogrammed Macrophages Ameliorate the Inflammatory Response and Protect Against the Neuroinflammatory Process in Parkinson's Disease Models.Aging Cell2025https://conductscience.org/library/papers/40146621PubMed
40119187Oxytetracycline and its Non-Antibiotic Derivative DOT Protect Midbrain Dopamine Neurons from Iron-Driven Oxidative Damage.Neurotox Res2025https://conductscience.org/library/papers/40119187PubMed
39770531Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39770531PubMed
39717965The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease.Future Med Chem2025https://conductscience.org/library/papers/39717965PubMed
39403917The Effectiveness and Safety Analysis of Duloxetine in Treating Comorbid Depression in Parkinson's Disease: A Retrospective Study.Actas Esp Psiquiatr2024https://conductscience.org/library/papers/39403917PubMed
39199337Novel Therapeutic Horizons: SNCA Targeting in Parkinson's Disease.Biomolecules2024https://conductscience.org/library/papers/39199337PubMed
39125607AR71, Histamine H3 Receptor Ligand-In Vitro and In Vivo Evaluation (Anti-Inflammatory Activity, Metabolic Stability, Toxicity, and Analgesic Action).Int J Mol Sci2024https://conductscience.org/library/papers/39125607PubMed
38962146Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?Front Hum Neurosci2024https://conductscience.org/library/papers/38962146PubMed
38561620Single-Cell Nuclear Sequencing Atlas Revealed the Induction of Parkinson's Disease by RELN+ Neuron 3 and the Gene Regulatory Network of MSRA.Curr Med Chem2025https://conductscience.org/library/papers/38561620PubMed

Download CSV of cited by

Genes28

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ADORA2A135PubTator's text mininghttps://conductscience.org/library/genes/135NCBI Gene
ADRB2154PubTator's text mininghttps://conductscience.org/library/genes/154NCBI Gene
COMT1312PubTator's text mininghttps://conductscience.org/library/genes/1312NCBI Gene
GBA12629PubTator's text mininghttps://conductscience.org/library/genes/2629NCBI Gene
GDNF2668PubTator's text mininghttps://conductscience.org/library/genes/2668NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
GRM52915PubTator's text mininghttps://conductscience.org/library/genes/2915NCBI Gene
HSPA83312PubTator's text mininghttps://conductscience.org/library/genes/3312NCBI Gene
HTR1A3350PubTator's text mininghttps://conductscience.org/library/genes/3350NCBI Gene
HTR2C3358PubTator's text mininghttps://conductscience.org/library/genes/3358NCBI Gene
IL103586PubTator's text mininghttps://conductscience.org/library/genes/3586NCBI Gene
IL1B3553PubTator's text mininghttps://conductscience.org/library/genes/3553NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
LRRK2120892PubTator's text mininghttps://conductscience.org/library/genes/120892NCBI Gene
MAOB4129PubTator's text mininghttps://conductscience.org/library/genes/4129NCBI Gene
MAPT4137PubTator's text mininghttps://conductscience.org/library/genes/4137NCBI Gene
MUC14582PubTator's text mininghttps://conductscience.org/library/genes/4582NCBI Gene
NEFL4747PubTator's text mininghttps://conductscience.org/library/genes/4747NCBI Gene
NRTN4902PubTator's text mininghttps://conductscience.org/library/genes/4902NCBI Gene
PDE10A10846PubTator's text mininghttps://conductscience.org/library/genes/10846NCBI Gene

See all 28 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37147404

GET https://conductscience.org/api/papers/v1/37147404/references?page=2